Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
21 p, 1.3 MB Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity / Velasco, Roser (Universitat Autònoma de Barcelona. Institut de Neurociències) ; Alemany, Montserrat (Institut d'Investigació Biomèdica de Bellvitge) ; Villagrán, Macarena (Institut d'Investigació Biomèdica de Bellvitge) ; Argyriou, Andreas A. (Neurology Department, "Saint Andrew's" State General Hospital of Patras)
Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. [...]
2021 - 10.3390/jpm11070669
Journal of Personalized Medicine, Vol. 11 (july 2021)  
2.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Safont, María José (Hospital General Universitario de Valencia) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital Clínico San Carlos (Madrid)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ; González, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202  
3.
7 p, 627.6 KB Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer / Wei, J. (Clinical Cancer Institute of Nanjing University) ; Costa, C. (Institut Dexeus) ; Shen, J. (Clinical Cancer Institute of Nanjing University) ; Yu, L. (TClinical Cancer Institute of Nanjing University) ; Sanchez, J. J. (Universidad Autónoma de Madrid. Departamento de Medicina Preventiva y Salud Pública) ; Qian, X (Clinical Cancer Institute of Nanjing University) ; Sun, X (Clinical Cancer Institute of Nanjing University) ; Zou, Z. (Clinical Cancer Institute of Nanjing University) ; Giménez-Capitán, Ana (Institut Dexeus) ; Yue, G. (Clinical Cancer Institute of Nanjing University) ; Guan, W. (Nanjing University. Department of General Surgery) ; Rosell, R. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Liu, B. (Clinical Cancer Institute of Nanjing University) ; Universitat Autònoma de Barcelona
Breast cancer susceptibility gene 1 (BRCA1) expression differentially affects outcome to platinum- and taxane-based chemotherapy. Mediator of DNA damage checkpoint protein 1 (MDC1), p53-binding protein 1 (53BP1), multiple myeloma SET domain (MMSET) and ubiquitin-conjugating enzyme 9 (UBC9) are involved in DNA repair and could modify the BRCA1 predictive model. [...]
2014 - 10.1038/bjc.2014.231
British Journal of Cancer, Vol. 110 (05 2014) , p. 2662-2668  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.